This clinical-stage biopharmaceutical company has seen a mixed track record when it comes to estimate revisions of 3 increases and 1 decrease over the last 30 days. Meanwhile, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
MacroGenics currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Investors interested in the medical industry may consider other well-placed stocks like Cardica Inc. (CRDC), Eagle Pharmaceuticals Inc. (EGRX) and ICU Medical, Inc. (ICUI). All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment